Sputnik V was the world's first coronavirus vaccine officially registered for emergency use on 11 August. Clinical trials ended in November, with an efficacy level of 91.4 percent, based on data from the first 16,000 trial participants that received both shots of the two-dose vaccine.
"Our vaccine has been tested more than enough. Mind that both Moderna and AstraZeneca followed our path", Gintsburg said.
According to researchers, Sputnik V is capable of building up immunity for more than two years.